"rarely appropriate," incorporating the best clinical and scientific evidence, cost-effectiveness data and the consensus of experts within the SCAI Peripheral Vascular Disease Committee.
The purpose of this update is to provide a focused review of new clinical evidence regarding EVT, to identify novel technologies and practice changes that have been introduced since the original documents were published and to provide updated recommendations.
| M E TH ODOL OGY
The definition of appropriate use (AUC) is largely consistent across technologies and procedures. AUC considers the risks and benefits of a procedure while applying this balance across clinically relevant scenarios. An appropriate diagnostic or therapeutic procedure is one in which the expected clinical benefit exceeds the risks of the procedure by a sufficiently wide margin such that the procedure is generally considered acceptable or reasonable [5, 6] . For renal arterial revascularization, the benefits included: blood pressure improvement, renal function improvement or stabilization, and improved cardiac destabilization syndromes (heart failure and angina exacerbations) weighed against the risks of the procedure. For lower extremity arterial revascularization, the benefits included: survival or health outcomes such as symptom improvement, limb salvage, functional status and/or quality of life, weighed against the risks of the procedure.
"Appropriate Care" implies that the benefits generally outweigh the risks of the procedure. The procedure is an effective option for individual care although not always required or necessary; the procedure is generally acceptable and reasonable for the indication.
"May Be Appropriate Care" describes an option that is generally accepted with variable levels of supporting evidence or expert consensus regarding the risk to benefit ratio. There may be utility in selected cases based upon clinical experience in the absence of comparative evidence. The appropriateness of a specific procedure in any individual must be determined by that patient's physician in consultation with the patient considering the risk to benefit ratio. This category of procedures may be acceptable and may be reasonable for the clinical scenario.
"Rarely Appropriate" care describes an option for the management of a patient with an adverse or uncertain risk to benefit ratio. The option is not commonly used as an effective therapy and the rationale for choosing this option needs to be documented. The procedure is recognized to be effective in selected situations but is not generally applied and is not generally reasonable for the indication. Procedures in this category require justification through the documentation of individual patient circumstances.
| AUC methodology and assumptions
1. The clinical scenarios chosen for this document are not intended to be all-inclusive. Not every clinical scenario can or will be addressed.
2. Lesion characteristics are arbitrarily divided into focal, intermediate, and diffuse for each anatomical subset as defined below.
3. When not specifically stated, assume that patients are being treated with guideline-directed medical therapy (GDMT).
Scenarios were scored independently of each other. There is no
"ranking" of indications. This means that two different scenarios regarding aorto-iliac intervention may be scored the same value (i.e., 7 (appropriate), even if the scenarios are different.
5. The cost of care was considered in determining appropriateness.
For example, a procedure that is ten-times more expensive than another, but equally effective, should be rated lower. Device cost, complication rates, durable patency and length of hospital stay all contribute to the cost of care. 6 . It is assumed that interventions are performed by the "average" interventionalist, who is credentialed by their hospital to perform the procedure being considered, and not the most experienced expert, nor the most recent graduate from fellowship training. In each of the depicted clinical scenarios, the assumption is made that the approach to EVT was carefully considered in terms of the clinical need, the opportunity for benefit, as well as the potential risks.
7. For device scenarios, assume the intention is to use the device as the ultimate or definitive device, regardless of lesion preparation.
Percutaneous transluminal angioplasty (PTA) can be chosen as the intended definitive treatment, even if it may be necessary to "bail out" with a stent. DCB can be chosen as the intended definitive treatment with the knowledge the lesion will be prepared and predilated with an uncoated balloon first. Rotational atherectomy can be considered as the definitive treatment modality if the procedure could not be completed without its use, an undilatable lesions for example, despite the need for subsequent PTA or stent placement to complete the procedure.
8. Rarely Appropriate (1-3) means that a particular procedure will be appropriate only in selected circumstances. It does not mean "never," although a score of 1 (one) is as close to never as one can get.
9. May Be Appropriate (4-6) means that a procedure is indicated under certain circumstances, and not in others.
10. Appropriate (7) (8) (9) means that a procedure is usually indicated, with a score of 9 (nine) representing usual care. 
| General definitions

| Definitions for infra-popliteal lesions
1. One-vessel infra-popliteal disease implies that two tibial arteries are without hemodynamically significant stenosis (70% or occlusion); Two-vessel infra-popliteal disease implies that one tibial artery is without hemodynamically significant stenosis or occlusion (tibioperoneal trunk disease affects both the posterior tibial and peroneal arteries which is consistent with two-vessel infra-popliteal disease); Three-vessel infra-popliteal disease implies that all three tibial arteries have hemodynamically significant stenosis and/or occlusion.
A focal infra-popliteal lesion is a discrete area of narrowing 4-cm
long. An intermediate infra-popliteal lesion is a continuous segment of disease 4-10 cm long. A diffuse infra-popliteal lesion is a continuous segment of disease >10 cm long.
| Renal interventional updates 2.3.1 | Introduction
Renal hypoperfusion leads to the activation of the renin-angiotensinaldosterone axis (Table 2) . This results in vasoconstriction, sodium and water retention, aldosterone secretion, and sympathetic nervous system activation [1, 7] , which in turn can lead to systemic hypertension or cardiac destabilization syndromes (flash pulmonary edema, refractory heart failure and/or unstable angina). Renal hypoperfusion may also lead to ischemic nephropathy and chronic kidney disease (CKD). There has been great interest in relieving renal hypoperfusion when it is secondary to atherosclerotic stenosis at the renal artery ostium and/or proximal aspect of the renal artery or arteries with stent deployment [8] . Table 3 summarizes the most current ACC/AHA guidelines update on renal intervention [9] . [1, [10] [11] [12] . A large multicenter randomized controlled CORAL (cardiovascular outcomes in renal atherosclerotic lesions) trial [13] demonstrated that for patients with hypertension and newly diagnosed renal artery stenosis, the most appropriate therapy was to maximize medical therapy before considering revascularization. The CORAL study found that the primary composite end point (death from cardiovascular or renal causes, myocardial infarction, stroke, hospitalization for congestive heart failure, progressive renal insufficiency, or the need for renal replacement therapy) in patients with renal artery stenosis (>60% diameter stenosis) and hypertension did not differ between groups treated with GDMT alone compared to GDMT with renal stenting [14] .
The CORAL trial has limitations similar to other previous comparative renal artery stent trials [15, 16] . These include enrolling patients with moderate hypertension receiving only two antihypertensive medications, not requiring maximally tolerated doses, and the majority of enrolled patients having moderate (68% diameter stenosis) renal artery stenosis and without hemodyanmic confirmation of the severity of obstruction.
At baseline, CORAL participants were taking 2.1 6 1.6 antihypertensive medications with a systolic blood pressure of 150 6 23 mm
Hg. At the conclusion of the trial, both the medical therapy cohort and the group that underwent renal revascularization had increased the number of medications required, 3.5 6 1.4 versus 3.3 6 1.5, respectively (P 5 ns) and both groups had comparable decreases in systolic blood pressure, 
| Clinical considerations
Several meta-analyses [22, 23] have shown that fewer antihypertensive medications are required to achieve desired blood pressure reduction following renal artery revascularization. Future trials may yield the most robust insights into the value of renal artery stenting if: they only enroll patients with hemodynamically-significant lesions, as determined by invasive measurement in a controlled, standardized fashion; if they include an assessment of anti-hypertensive medication compliance; and if they are based on accurate blood pressure assessment, including ambulatory 24-h blood pressure monitoring.
It is difficult to demonstrate the cost-effectiveness of renal artery stenting without unequivocal clinical benefit in the populations studied.
The few available cost-effectiveness analyses have predated publication of most randomized controlled trials. Nevertheless, a German economic analysis of hypertensive patients with renal artery stenosis used a decision analytic model to predict 3-year costs [24] . They observed a cost benefit of e11,663 ($13,044), e36,454 ($40,771), e51,752
($57,881) and e78,766 ($88,095), for stenting, surgery, PTA and medical therapy, respectively, and concluded that a strategy of primary renal stenting was the most cost-effective strategy in this setting.
| Technical considerations
The increasing adoption of transradial arterial access for coronary and peripheral vascular intervention has inspired significant interest into the application of this approach for renal artery stenting. Because most renal arteries have a natural downward angulation, they may often be easier to engage with a catheter advanced from a superior approach (i.e., the arm) compared with a catheter directed from the femoral approach. The availability of 125 cm guiding catheters and balloons and stents with longer shafts (e.g., 150 cm) make renal artery stenting from the transradial approach feasible for most patients.
| Aorto-iliac interventional updates 2.4.1 | Introduction
The goals of therapy for patients with aorto-iliac atherosclerotic disease have not changed (Table 4 The CLEVER investigators conducted a 5-year cost-effectiveness analysis using the 18-month follow up data [26] . Assuming that the quality of life benefits associated with each treatment strategy would dissipate over time, they calculated incremental cost-effectiveness The updated ACC/AHA Peripheral Artery Disease guidelines [28] continue to support EVT, with primary or provisional stenting, as firstline therapy for symptomatic aorto-iliac occlusive disease states that "Endovascular procedures are effective as a revascularization option for patients with lifestyle limiting claudication and hemodynamically significant aorto-iliac occlusive disease". Because of its high success rates and lower morbidity/mortality compared to surgical revascularization, EVT, with primary or provisional stenting may be considered a first-line treatment strategy for aorto-iliac disease [29] [30] [31] [32] .
| Anatomic considerations
The TASC-II document [33] , recently updated [34] , has traditionally been used to describe the anatomic characteristics of lower extremity atherosclerotic disease as they relate to therapeutic options ( Figure   2 ). The initial writing group had a preference for surgical intervention in more anatomically complex lesions (TASC C/D). Over the decade since the document's publication, however, advances in technology and operator technique now permit safe, effective, and relatively durable treatment of even the most complex (TASC C/D) lesions with EVT [34] . A recent large retrospective study from Japan [35] demonstrated that in a cohort of 2,096 patients with complex aorto- The study did confirm the technical challenges associated with EVT in complex lesion subsets, yielding a lower procedural success rate (91.6% vs. 99.3%, P < 0.01) and a greater rate of procedure-related complications (11.1% vs. 5.2%, P < 0.01) in the TASC D group when compared to the TASC A-C lesion cohort.
The STents versus AnGioplasty (STAG) [36] trial randomized primary stenting against PTA for iliac occlusion and was stopped early due to a high rate of embolic complications in the PTA treatment group. Primary stenting improved technical success and lowered major 
| Technical considerations
Both nitinol and stainless steel self-expanding stents perform well in the iliac location with low restenosis rates [41] [42] [43] [44] [45] . A recent multicenter trial randomized 660 patients with Rutherford Classification (RC) 1-4 to treatment with either a balloon expandable (BE) or self-expanding (SE) stent. The primary patency at 12 months favored the SE over BE with an SE restenosis rate of 6.1 and 14.9% after BE (P 5 0.006) [46] .
Usually, balloon-expandable stents are chosen for ostial lesions where precise placement is a priority, or when significant recoil is anticipated, while self-expanding stents more readily contour to tapering and tortuous vessels. While drug-eluting stents (DES) and drug coated balloons (DCB) have not been evaluated in iliac arteries, in highly selected cases, they may be useful in an appropriately sized vessel with in-stent restenosis [47] .
The overall results for TASC B, C, and D lesions in the COBEST (COvered versus Balloon Expandable Stent Trial) trial [48] did not find any differences for binary restenosis or freedom from occlusion at 18 months between the covered and non-covered balloon expandable stents. However, the more complex TASC C and D lesion cohort of that trial did have an improved primary patency rate when covered balloonexpandable stents were used as compared to bare metal stents (BMS).
The recently published 5-year data from this trial continue to demonstrate an advantage for covered versus BMS in TASC C and D iliac artery lesions [49] . A recent meta-analysis of RCTs and observational studies found that covered stents in iliac arteries were not associated with a significant improvement in primary patency, but were associated with a higher ankle-brachial index and a lower reintervention rate [50] .
There has been rapid adoption of transradial access for coronary angiography and interventions. There is growing interest in the transradial approach for renal, mesenteric and lower extremity intervention in suitable patients [51, 52] . Pre-procedural planning is required to ensure that large diameter balloons and stents on shaft lengths of at least 150 mm may be delivered through radial access arterial sheaths (4-7
French) [53] . In the patient presenting with CLI, with threatened limb or tissue loss, the objective is to restore perfusion of the ischemic tissue as rapidly as possible, in order to relieve the ischemia, prevent or limit the amount of tissue loss, and restore ambulation. In treating patients with CLI, durable patency remains desirable; but once the wound has healed, restenosis may not place the limb in jeopardy unless re-injury occurs.
Several trials have shown significant patient benefit with OMT and SET therapy in relieving symptoms of claudication at 1 year [25, 55, 56] . [28] . These recommendations emphasize that the benefit of EVT in claudicants is related to durable patency, which is influenced by numerous patient and lesion specific that "the choice of endovascular therapy as a revascularization approach for claudication due to femoral-popliteal disease should include a discussion of outcomes, addressing the risk of restenosis and repeat intervention, particularly for lesions with a poor likelihood of long-term durability" [28, 34] .
Common femoral endarterectomy (CFE) has been the gold standard for the treatment of common femoral arterial (CFA) disease based upon single center series and expert consensus [63] . However, a recent report from a large national database (American College of Surgeons:
National Surgical Quality Improvement Program [ACS-NSQIP]) on 1,843 patients undergoing CFE found an overall 15% risk of combined mortality/morbidity (3.4% mortality, 8% wound-related complications, 10% surgical take-backs) [64] . They concluded that CFE was not as "benign" a procedure as has been previously believed.
Recently published evidence supports an endovascular-first approach to CFA disease with registry data reporting mortality/morbidity rates of 7.2% [65] . Long-term, 5-year follow-up of CFA stenting demonstrates a very favorable freedom from target lesion revascularization (TLR) of 79%. The Endovascular Versus Open Repair of the Common Femoral Artery (TECCO)" trial (ClinicalTrials.gov identifier NST01353651) randomized 117 patients comparing CFE to EVT for isolated CFA lesions [66] . The primary outcome, the morbidity and mortality rate within 30 days, occurred in 16 of 61 patients (26%) in the CFE group and 7 of 56 patients (12.5%) in the EVT group (odds ratio, 2.5; 95% CI, 0.9 to 6.6; P 5 0.05). The mean duration of hospitalization was significantly lower in the EVT group (3.2 6 2.9 days versus E100 | 6.3 6 3 days; P < 0.0001). At 24-months, the sustained clinical improvement, the primary patency rate, and the target lesion and extremity revascularization rates were not different in the two groups.
This trial demonstrates that for de-novo CFA lesions, EVT can achieve comparable 2-year patency rates with CFE and offer significantly lower 30 day morbidity and mortality rates.
| Clinical considerations
Clinically relevant femoral-popliteal disease is defined as a 70% diam- 
| Technical considerations
There have been significant technological advances and further devel- 20 .6% in the PTA arm; P < 0.001). These benefits persisted at 24 months with higher primary patency (78.9% vs. 50.1%; P < 0.001) and lower rates of clinically driven TLR were 9.1% and 28.3% (P < 0.001) [75] . A formal analysis based on the 2-year results suggests a 70-80% likelihood that the DCB is an economically attractive strategy [68] . The 1-year patency in the VIASTAR group was 70.8% by intention to treat with no statistical advantage over the BMS group (55.1%, P 5 0.11), but when analyzed by treatment received, the covered stent's 1-year patency was 78.1%, which was superior to BMS (53.5%, P 5 0.009) [82] . The patency rates for the covered stent fell considerably at 2 years (63.1%) [84] and even further at 3 years (24.2%) [83] .
| Non-stent options
There is no comparative evidence supporting directional, rotational or orbital atherectomy as a superior treatment to PTA alone in de novo femoral-popliteal lesions. All studies to date involving these modalities respectively. Overall, ELA 1 PTA was associated with a 52% reduction in TLR for the treatment of femoral-popliteal ISR.
Another trial [89] of ELA for the treatment of ISR involved CLI patients with occlusion of the femoral-popliteal segment secondary to ISR. These 48 patients were randomized to DCB vs. ELA 1 DCB. The results suggest that debulking of the ISR tissue prior to the use of DCB was beneficial in this challenging patient population. In the ELA 1 DCB group, the patency rates at 6 and 12 months (91.7 and 66.7%,) were significantly higher (P 5 0.01) than in the DCB only patients (58.3 and 37.5%, respectively). TLR at 12 months was 16.7% in the ELA 1 DEB group and 50% in the DEB only group (P 5 0.01).
2.6 | Infra-popliteal interventional update
| Introduction
Revascularization of infra-popliteal PAD is generally limited to those patients presenting with critical limb ischemia (CLI) where in-line flow to the foot is the standard of care for wound healing and/or resolution of rest pain [90] (Table 6 ). In general, nonambulatory patients with a 
| Anatomic considerations
Patients with CLI typically have disease involving multiple levels (i.e., aorto-iliac, femoral-popliteal and infra-popliteal), but <10% of patients with CLI have hemodynamically significant disease at all three levels.
The updated 2015 TASC document includes, for the first time, an anatomic classification for infra-popliteal atherosclerotic disease ( Figure 4) [34]. Infrainguinal PAD can be further subdivided into those with predominantly isolated infra-popliteal disease (33%) and those with both femoral-popliteal and infra-popliteal disease (67%) [93] [94] [95] [96] . Isolated infra-popliteal disease is mainly seen in the elderly (>80 years old), diabetic, or patients with advanced stages of chronic kidney disease [94] .
This arterial bed consists of relatively small caliber arteries, which are often calcified and associated with diffuse, multi-segment disease [4] .
These patients are at higher risk for amputation and have a shorter amputation-free survival (AFS) compared to those with combined femoral-popliteal and infra-popliteal disease [95] . Prior to considering infra-popliteal intervention, all hemodynamically significant inflow disease should be treated to normalize inflow to the infra-popliteal circulation. Then, if deemed clinically necessary, one may proceed with revascularization of the infra-popliteal disease.
However, even if major amputations are avoided, complete wound healing may be elusive with inframalleolar disease. Recent evidence shows that delayed, and/or incomplete wound healing adversely affects quality of life and social rehabilitation. Several trials have also demonstrated the negative influence of inframalleolar disease on wound healing rates [97, 98] .
| Clinical considerations
Patients with infra-popliteal disease and claudication should be preferentially treated with cilostazol (if a candidate), a supervised exercise due to isolated infra-popliteal artery disease is unknown" [28] .
Infra-popliteal EVT is generally reserved for patients with CLI. For patients with claudication, only moderate to severe (50% diameter stenosis) lesions and multivessel tibial disease (2 tibial vessels) should be considered for revascularization. The goals of therapy for CLI patients (Rutherford 4-6) with infra-popliteal arterial disease include:
relieving pain, healing ulcerations, preventing major amputation, improving the patient's QOL, and prolonging survival [4] . Angiographically, severe infra-popliteal stenosis is defined as a luminal diameter stenosis of 70% in at least one infra-popliteal artery [95, 99, 100] .
Moderate stenosis is defined as a luminal reduction of 50-69% and mild stenosis is defined as a luminal reduction of <50%. Obstructive disease in the below-knee popliteal artery limits blood flow to the three tibial vessels (anterior, posterior and peroneal) and is equivalent to three vessel disease, while narrowing of the tibioperoneal trunk affects two tibial arteries (peroneal and posterior tibial) and is equivalent to two-vessel disease.
A focal infra-popliteal lesion is a discrete area of narrowing 4 cm
long. An intermediate infra-popliteal lesion is a continuous segment of disease >4 to 10 cm long. A diffuse infra-popliteal lesion is a continuous segment of disease >10 cm long [63] .
FIG URE 4
Trans-atlantic inter-society consensus for the management of peripheral arterial disease (TASC) classification of infra-popliteal lesions. The unshaded area represents the target lesion; area inside the shaded rectangle represents typical background disease ( Figure 3 , reproduced with permission) [33] E104 | Infra-popliteal intervention procedural success is commonly defined as the re-establishment of direct "in-line" pulsatile flow to the foot. It is currently unknown whether healing rates are improved when in-line flow to the foot is established through more than one artery, but maximizing blood flow through more than one artery is particularly attractive in patients with inadequate collateral circulation, disease of the plantar arch vessels, or limb-threatening ischemia [4] .
An angiosome is a vascular territory supplied by a specific source artery and was a principle originating from the plastic surgery literature.
This concept is based on areas of the foot (angiosomes) identified by injection of dye into cadaveric lower limbs without arterial insufficiency and therefore does not take into consideration any collateral circulation which is often present in CLI patients. There remains uncertainty regarding the value of angiosome-guided revascularization with some studies finding no correlation between the angiosome-directed concept and lower limb revascularization outcomes [101] [102] [103] . and other studies showing improved healing rates when compared to revascularization of the non-angiosome territory, particularly if there is poor pedal arch collateralization [98, [104] [105] [106] . In a small retrospective report, direct revascularization (angiosome based) versus indirect revascularization with good collateral circulation had similar outcomes whereas, indirect revascularization with poor collateral circulation fared the worst [107] . However, realistically the angiosome-based revascularization strategy may be limited by the length and/or complexity of underlying disease, the extent of collateralization, and the anatomic variability among patients, including anatomic anomalies [94] .
The cost-effectiveness of infra-popliteal intervention is difficult to ascertain without robust randomized data. Using a Markov simulation model, Barshes et al. examined various treatment strategies for patients with CLI and compared these to wound care plus amputation as needed [108] . They determined that endovascular intervention and surgical bypass with endovascular revision as needed were more effective and less costly than wound care with or without amputation as long as the initial wound healing rates were 50% and 70%, respectively.
The relative cost-effectiveness of an endovascular or surgical-first strategy is being determined in the ongoing BEST-CLI trial [109] .
| Technical considerations
When focal disease of the infra-popliteal arteries required intervention, stenting with a coronary balloon expandable BMS stents was the primary revascularization strategy [110] . PTA with bail-out stenting for an unsatisfactory PTA result with a self-expanding stent, has been com- Limb Ischemia) study [111] . Ninety-two patients with infra-popliteal PAD and severe claudication or CLI were randomized 1:1 to either primary or provisional stenting with a self-expanding nitinol stent (Astron Pulsar/Pulsar-18 nitinol stent, Biotronik, Lake Oswego, OR) between DES (60%) and BMS (56%) at 1 year, and there were very few amputations. DES had superior patency (DES 85% versus BMS 54%, P 5 0.0001) and freedom from TLR (DES 91% versus BMS 66%, P 5 0.001) [112] .
The YUKON-BTX (YUKON-Drug-Eluting Stent Below the Knee) trial [124] randomized 161 patients with severe claudication and CLI to infra-popliteal treatment with BMS or DES (Sirolimus eluting YUKON stent, Translumina, Hechingen, Germany) [124] . Primary patency at 1 year for the DES group was 80.6% versus 55.6% with BMS (P 5 0.004).
At 3 years of follow-up there was significant clinical benefit for the DES group for event-free survival (DES 65.8% versus 44.6% for BMS, P 5 0.02), reduced amputation rates (DES 2.6% versus BMS 12.2%, P 5 0.03) and TLR rates (DES 9.2% versus BMS 20% (P 5 0.06) [116] .
The IDEAS (Infra-popliteal Drug-Eluting Angioplasty Versus Stenting) Randomized Controlled Trial [114] compared a paclitaxel DCB (IN.
PACT Amphirion (Medtronic, Brescia, Italy) to DES in long (>70 mm) infra-popliteal lesions in patients with Rutherford classes 3 to 6. Fifty patients were randomized to infra-popliteal DCB angioplasty (25 arteries in 25 limbs; PCB group) or primary DES placement (30 arteries in 27 limbs; DES group). At 6 months, the angiographic restenosis rate was significantly lower in DES (28% versus 57.9% in DCB; P 5 0.046).
There were no significant differences with regard to TLR (7.7% in DES KLEIN ET AL.
| E105 versus 13.6% in DCB; P 5 0.65). In this comparison for longer below knee lesions, DES were associated with significantly reduced restenosis rates at 6 months compared to DCB.
The PADI (Percutaneous transluminal Angioplasty versus Drug eluting stents for Infra-popliteal lesions) trial was designed to compare the performance of paclitaxel-eluting DESs and PTA-BMS of infrapopliteal lesions in a population consisting solely of CLI patients [117] .
Recently, the 5-year follow-up data were published confirming the long-term advantage of coronary paclitaxel DES over a PTA with provisional BMS stenting (PTA-BMS) for RC class 4 patients with infrapopliteal lesions. The 5-year clinical outcomes of amputation and event-free survival (survival free from major amputation or reintervention) the DES arm was superior to the PTA-BMS group (31.8% versus 20.4%, P 5 0.043; and 26.2% versus 15.3%, P 5 0.041, respectively).
Survival rates were comparable. The results showed higher preserved patency rates after DESs than after PTA-BMS at 1, 3, and 4 years of follow-up. These data, including several meta-analyses, provide convincing evidence (Class 1, LOE B) favoring infra-popliteal DES over PTA and BMS for (1) improved patency, (2) reduced re-interventions, (3) reduced amputation, and (4) improved event-free survival [116, [118] [119] [120] [121] [122] ].
| Drug-coated balloons
The evidence supporting the use of DCB for infra-popliteal lesions is group. There was a non-significant trend toward higher amputation rates in the DCB (8.8%) compared to the PTA group (3.6%, P 5 0.08).
There are no data to suggest that procedures on infra-popliteal arteries should be performed to prevent CLI. This is confirmed in the recent ACC/AHA guidelines that state: "Endovascular procedures should not be performed in patients with PAD solely to prevent progression to CLI." [28] This is based on data showing that though feared, the rate of progression to CLI and/or amputation remains relatively low [126] [127] [128] . 
